---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008300"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:06:19.321283+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam provides pipeline update; cash ~$729M; EMA decision expected 2H26

## Summary
- Unaudited cash, cash equivalents and marketable securities ~$729M as of Dec 31, 2025.
- EMA approval decision for obicetrapib monotherapy and FDC expected in 2H26.
- PREVAIL CVOT overall MACE event rate tracking in line with BROADWAY; fully enrolled with >9,500 patients.
- First patient enrolled in RUBENS Phase 3 trial for metabolic syndrome; topline data expected year-end 2026.
- Plans to initiate first dedicated Alzheimer's trial in 2026 based on positive biomarker data.

## SEC filing metadata
- accession: 0001193125-26-008300
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/0001193125-26-008300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/nams-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008300
- JSON: https://secwatch.observer/filing/0001193125-26-008300.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.